$18.35
0.54%
NYSE, Aug 29, 10:15 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock price

$18.35
+3.96 27.52% 1M
+7.18 64.28% 6M
+6.24 51.53% YTD
+3.06 20.01% 1Y
+3.04 19.86% 3Y
-10.71 36.85% 5Y
-17.65 49.03% 10Y
-17.65 49.03% 20Y
NYSE, Closing price Fri, Aug 29 2025
-0.10 0.54%
ISIN
US28414H1032
Symbol
ELAN
Industry

Key metrics

Basic
Market capitalization
$9.1b
Enterprise Value
$12.8b
Net debt
$3.7b
Cash
$539.0m
Shares outstanding
496.7m
Valuation (TTM | estimate)
P/E
21.1 | 20.3
P/S
2.0 | 1.9
EV/Sales
2.9 | 2.7
EV/FCF
36.8
P/B
1.4
Financial Health
Equity Ratio
48.3%
Return on Equity
5.5%
ROCE
1.7%
ROIC
1.3%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$4.5b | $4.7b
EBITDA
$736.0m | $868.8m
EBIT
$209.0m | $680.8m
Net Income
$434.0m | $449.9m
Free Cash Flow
$347.0m
Growth (TTM | estimate)
Revenue
-0.2% | 5.7%
EBITDA
-12.6% | 11.7%
EBIT
-30.3% | 171.3%
Net Income
134.6% | 33.1%
Free Cash Flow
-18.4%
Margin (TTM | estimate)
Gross
54.7%
EBITDA
16.4% | 18.5%
EBIT
4.7%
Net
9.7% | 9.6%
Free Cash Flow
7.7%
More
EPS
$0.9
FCF per Share
$0.7
Short interest
6.8%
Employees
9k
Rev per Employee
$480.0k
Show more

Is Elanco Animal Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

15x Buy
71%
6x Hold
29%

Analyst Opinions

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,484 4,484
0% 0%
100%
- Direct Costs 2,030 2,030
1% 1%
45%
2,454 2,454
1% 1%
55%
- Selling and Administrative Expenses 1,364 1,364
5% 5%
30%
- Research and Development Expense 354 354
4% 4%
8%
736 736
13% 13%
16%
- Depreciation and Amortization 527 527
3% 3%
12%
EBIT (Operating Income) EBIT 209 209
30% 30%
5%
Net Profit 434 434
135% 135%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Elanco Animal Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
5 days ago
Coalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis CARMEL, Ind. , Aug. 27, 2025 /PRNewswire/ -- Splenda®, a leading global health and wellness brand in sweeteners, has teamed up with Elanco and HATCH, as well as other partners to sponsor Nutrition Secure Indianapolis, a fir...
Neutral
PRNewsWire
6 days ago
NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (XNYS: BHLB) is acq...
Neutral
PRNewsWire
6 days ago
GREENFIELD, Ind. , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025.
More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office United States
CEO Jeffrey Simmons
Employees 9,225
Founded 1954
Website www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today